LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
IndustriesMetabolomics
ManufacturerAgilent Technologies
Optimizing Data‑Dependent Acquisition (DDA) for Untargeted Metabolomics on the Agilent Revident LC/Q‑TOF — Technical Overview Summary
Significance of the topic
High‑confidence metabolite annotation in untargeted LC‑MS workflows is limited chiefly by incomplete and low‑quality MS/MS coverage. Optimizing data‑dependent acquisition (DDA) strategies increases the number of informative fragmentation spectra per injection and improves library matching confidence, which accelerates metabolite identification and downstream biological interpretation. The combination of robust HILIC separation, informed precursor selection, and iterative acquisition strategies yields richer MS/MS datasets for discovery metabolomics.
Objectives and overview of the study
The work presents a practical guide to optimize key DDA parameters on an Agilent Revident LC/Q‑TOF running MassHunter DA (v12.1+). Main aims were to: (1) compare Auto MS/MS and the newer Directed MS/MS modes; (2) define optimal settings for precursor thresholds, MS1/MS2 acquisition rates, number of precursors per cycle, active exclusion rules, and purity/centroiding; and (3) demonstrate exclusion‑list strategies and iterative injection logic to boost MS/MS coverage while balancing spectral quality for library matching.
Methodology and instrumentation
Sample preparation and chromatography
Mass spectrometry and software
Key acquisition parameters and rationale
Main results and discussion
Exclusion list strategies and MS/MS coverage
Trade‑offs between acquisition rate and spectral quality
Practical recommendations resulting from the study
Benefits and practical applications
Optimized DDA methods described here enable substantially higher MS/MS coverage and better prioritization of biologically relevant precursors. This improves confidence in spectral library matches and expedites metabolite annotation workflows in discovery studies, biomarker research, and semi‑targeted follow‑up experiments. Directed MS/MS supports targeted interrogation of statistically significant features, while iterative Auto MS/MS maximizes total coverage for broad discovery work.
Future trends and applications
- Deeper automation of exclusion/preferred list generation from initial MS1 batches (integration with statistical pipelines) will streamline semi‑targeted studies and reduce manual curation.
- Advances in adaptive acquisition algorithms (real‑time prioritization, smarter variable acquisition) could further improve the balance between coverage and spectral quality.
- Improved spectral libraries with multi‑collision energy entries and community‑driven curation will increase identification confidence, particularly for low‑abundance metabolites.
- Integration with ion mobility, orthogonal separation, and enhanced informatics (AI‑assisted spectral annotation) will expand identification rates and structural insight from DDA datasets.
Conclusion
Methodical optimization of DDA parameters on the Agilent Revident LC/Q‑TOF—covering acquisition rates, precursor selection rules, exclusion strategies, and data storage settings—substantially improves MS/MS coverage and annotation potential in untargeted metabolomics. Directed MS/MS is effective for focused, biologically relevant lists, while iterative Auto MS/MS at high acquisition rates maximizes overall coverage at the cost of some loss in library match score. Choosing settings requires explicit trade‑offs tailored to chromatographic behavior, sample complexity, and the identification goals of the study.
Instrumentation used
- Agilent Revident LC/Q‑TOF with Agilent MassHunter Data Acquisition for TOF/Q‑TOF LC/MS v12.1 (and later).
- Agilent 1290 Infinity II Bio LC (compatible with Infinity III Bio LC).
- InfinityLab Poroshell 120 HILIC‑Z (2.1 × 150 mm, 2.7 µm).
- Agilent ZORBAX Eclipse Plus C18 column (2.1 × 50 mm, 1.8 µm) for plant extract tests.
- Agilent Captiva EMR cartridges for plasma extraction.
- MassHunter Qualitative Analysis v12.0/13.0 for library matching and scoring.
References
- Sumner LW, Amberg A, Barrett D, et al. Proposed Minimum Reporting Standards for Chemical Analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics. 2007;3(3):211–221.
- Schymanski EL, Jeon J, Gulde R, et al. Identifying Small Molecules via High Resolution Mass Spectrometry: Communicating Confidence. Environ Sci Technol. 2014;48(4):2097–2098.
- Durham SD, Yannel KE, Simmermaker C, Van de Bittner G, Bertram L, Cuthbertson D, Klein C. An End‑to‑End Untargeted LC/MS Workflow for Metabolomics and Lipidomics. Agilent Technologies application note, publication 5994‑8371EN, 2025.
- Yannell KE, Durham S, Simmermaker C, Van de Bittner G. Uncovering More Biological Insights in Your Samples with Routine LC/Q‑TOF Workflows for Metabolites and Lipids. Agilent Technologies ASMS poster ThP‑085, 2024.
- Zhao L, Juck M. Protein Precipitation for Biological Fluid Samples Using Agilent Captiva EMR–Lipid 96‑Well Plates. Agilent application note 5991‑9222EN, 2018.
- Yannell KE, Simmermaker C, Van de Bittner G, Cuthbertson D. An End‑to‑End Targeted Metabolomics Workflow. Agilent application note 5994‑5628EN, 2023.
- Ferrer I, Thurman EM, Zweigenbaum JA. Auto MS/MS and Identification of Unknowns in Water Samples. Agilent technical overview 5994‑0322EN, 2018.
- Wu L, Wong DL. In‑depth Peptide Mapping with Iterative MS/MS Acquisition on the Agilent 6545XT AdvanceBio LC/Q‑TOF. Agilent application note 5991‑8633EN, 2020.
- Koelmel J, Sartain M, Salcedo J, et al. Improving Coverage of the Plasma Lipidome Using Iterative MS/MS Data Acquisition Combined with Lipid Annotator Software and 6546 LC/Q‑TOF. Agilent application note 5994‑0775EN, 2020.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.